Anastrozole
978-613-3-88175-4
6133881755
64
2010-11-13
29.00 €
eng
https://images.our-assets.com/cover/230x230/9786133881754.jpg
https://images.our-assets.com/fullcover/230x230/9786133881754.jpg
https://images.our-assets.com/cover/2000x/9786133881754.jpg
https://images.our-assets.com/fullcover/2000x/9786133881754.jpg
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Anastrozole (INN, trade name Arimidex, AstraZeneca) is a drug used to treat breast cancer after surgery and for metastases in post-menopausal women. Anastrozole is an aromatase inhibitor, which means that it interrupts a critical step in the body's synthesis of estrogen. Some breast cancer cells require estrogen to grow, and eliminating estrogen suppresses their growth. Annual sales approx $2.2bn. Patent expires 2010 in the US however, the generic form is available in some other markets. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial was an international randomised controlled trial of 9366 women with localized breast cancer who received either anastrozole, tamoxifen, or both for five years, followed by five years of follow-up. After more than 5 years the group that received anastrozole had significantly better clinical results than the tamoxifen group.
https://www.morebooks.de/books/ru/published_by/alphascript-publishing/2/products
Медицина
https://www.morebooks.de/store/ru/book/anastrozole/isbn/978-613-3-88175-4